

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/839,946
				Filing Date	April 19, 2001
				First Named Inventor	WILLIAMS, L. David
				Art Unit	1652
				Examiner Name	SAIDHA, T.
Sheet	1	of	1	Attorney Docket Number	2057.0090003/BJD/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL5	Patent Abstract of Japan, English language abstract of JP 55-135590 A (Document FP1)	
	NPL6	Patent Abstract of Japan, English language abstract of JP 62-55079 A (Document FP2)	
	NPL7	Francis, G.E., <i>et al.</i> , "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques," <i>Int. J. Hematology</i> 68:1-18, Elsevier Science Ireland Ltd. (1998)	
	NPL8	Kral, L.G., <i>et al.</i> , "Cloning a cDNA for <i>Drosophila melanogaster</i> urate oxidase," <i>Gene</i> 45:131-137, Elsevier Science Publishers B.V. (1986)	
	NPL9	Wang, L.-W.C., and Marzluf, G.A., "Purification and Characterization of Uricase, a Nitrogen-Regulated Enzyme, from <i>Neurospora crassa</i> ," <i>Archs. Biochem. Biophys.</i> 201:185-193, Academic Press, Inc. (1980)	

976423v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.